TP53 and cancer: These signatures were firstly analyzed in a small number of frequently mutated cancer genes like the TP53, however with the rapid development of the massively parallel sequencing technology, it has overcome the scale limitations, thus tens of thousand of variations can be identified in a cancer genome.